FDA “Drug Watch” Early Warnings Will Have Lasting Negative Effect, PhRMA Says

A “Drug Watch” listing can do lasting damage to a brand’s reputation based on inadequate data, PhRMA Chief Medical Officer Antony says. The PhRMA exec uses an “extreme” example to highlight his point: imagine “someone reporting that they had early information that you may be a child molester.”